(lp0
S'Keep An Eye On Rexahn Pharmaceuticals Inc  This Year Insider Financial - Mar 13, 2017 Rexahn Pharmaceuticals, Inc.  ran up towards the end of last week on basically no news, and is running again early session in the US on Monday.The Epic Rise of Rexahn Pharmaceuticals, Inc.  - The Oracle DispatchStock under Discussion: Rexahn Pharmaceuticals, Inc.  - Post Registrar'
p1
aS"Rexahn Pharmaceuticals, Inc.  Announces Full Year 2016 Financial Results Smarter Analyst - Feb 27, 2017 Rexahn Pharmaceuticals, Inc.  announced financial results for the year ended December 31, 2016 and provided an update on the Company's clinical development programs.Shares of Rexahn Pharmaceuticals, Inc.  Plunge -4.8% - Energy IndexTrading updates about Stock: Rexahn Pharmaceuticals, Inc.  - Is stories"
p2
aS'Quick Review on Trend Indicator Levels: Rexahn Pharmaceuticals Inc  Rives Journal - 16 hours ago Investors are keeping a close eye on levels of Rexahn Pharmaceuticals Inc . The Average Directional Index or ADX is a technical analysis indicator used to describe if a market is trending or not trending.'
p3
aS"What are Analyst's Indicators for Catabasis Pharmaceuticals, Inc. (CATB ... The USA Commerce - Mar 13, 2017 Shares of Catabasis Pharmaceuticals, Inc.  surged 53.38% to $2.04. During the trading on 03/10/2017, Company's stock ranged from $1.58 to $2.76. The relative strength index or RSI highlights overbought  and oversold (below&nbsp;...Biotech Stocks Worth a Closer Look: Catabasis Pharmaceuticals, Inc. (NASDAQ ... - The Voice RegistrarBiotech Stocks Worth Chasing: Catabasis Pharmaceuticals, Inc. , Rexahn ... - The Independent Republic"
p4
aS"Is It Time to go for Rexahn Pharmaceuticals, Inc. , TG Therapeutics, Inc ... StockNewsJournal - Mar 10, 2017 ROI deals with the invested cash in the company and the return the investor realize on that money based on the net profit of the business.Rexahn Pharmaceuticals, Inc.'s  stock price is Worth at $0.32 while ... - Hot Stocks PointRexahn Pharmaceuticals, Inc. : A Detailed Look at its Institutional Ownership - Post Analyst"
p5
aS'Rexahn Pharmaceuticals, Inc.  Initiates Clinical Trial to Evaluate the ... Smarter Analyst - Feb 23, 2017 Rexahn Pharmaceuticals, Inc.  announced that is has begun enrolling patients into a Phase IIa clinical study of Supinoxin in metastatic triple negative breast cancer .'
p6
aS'Rexahn Pharmaceuticals, Inc.  And Its Technical Chart Creates A ... NY Stock News - 16 hours ago Rexahn Pharmaceuticals, Inc.  has created a compelling message for traders in the most recent trading. That message has grown stronger as the technical chart setup has developed into a more composite picture for the stock.'
p7
aS'Crazy Volume Spikes for: Rexahn Pharmaceuticals, Inc.  FactsReporter - 20 hours ago Rexahn Pharmaceuticals, Inc. on 11/07/2016 reported its EPS as $0.01 with the analysts projecting the EPS of the stock as $-0.03.'
p8
aS'Swinging Stock Alert: Rexahn Pharmaceuticals, Inc.  StandardOracle - 19 hours ago Rexahn Pharmaceuticals, Inc.  added 2.54% to reach $0.46 in the previous trading session. Overall, 31.66 Million shares exchanged hands versus its average trading volume of 3.2 Million shares.'
p9
aS"Most Active Stock Update: Rexahn Pharmaceuticals, Inc.  HugoPress - 17 hours ago MLV &amp; Co. Initiates Coverage on Rexahn Pharmaceuticals, Inc. 's stock to Buy with the price target of $1.3."
p10
a.